Follow-Up of SARS-CoV-2 Antibody Levels in Belgian Nursing Home Residents and Staff Two, Four and Six Months after Primary Course BNT162b2 Vaccination.
COVID-19 vaccination
SARS-CoV-2 antibodies
nursing home residents
nursing home staff
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
22 Aug 2024
22 Aug 2024
Historique:
received:
21
06
2024
revised:
20
08
2024
accepted:
21
08
2024
medline:
31
8
2024
pubmed:
31
8
2024
entrez:
29
8
2024
Statut:
epublish
Résumé
When COVID-19 vaccines were implemented, nursing home residents (NHRs) and staff (NHS) in Belgium were prioritized for vaccination. To characterize the vaccine response over time in this population and to identify poorly responding groups, we assessed antibody concentrations two (T1), four (T2) and six months (T3) after primary course BNT162b2 vaccination in six groups of infection-naive/infection-primed NHRs/NHS, with/without comorbidity (NHRs only). Participant groups (N = 125 per group) were defined within a national serosurveillance study in nursing homes, based on questionnaire data. Dried blood spots were analyzed using ELISA for the quantification of SARS-CoV-2 S1RBD IgG antibodies. Among all groups, antibody concentrations significantly decreased between T1 and T2/T3, all with a ≥70% decrease at T3, except for infection-primed staff (-32%). Antibody concentrations among infection-naive NHRs were 11.96 times lower than those among infection-primed NHR, while the latter were comparable (x1.05) to infection-primed NHS. The largest proportion [13% (95% CI: 11-24%)] of vaccine non-responders was observed in the group of infection-naive NHRs with comorbidities. A longer interval between infection and vaccination (≥3 months) elicited higher antibody responses. Our data retrospectively show the necessity of timely COVID-19 booster vaccination. Infection-naive NHRs require special attention regarding immune monitoring in future epidemics or pandemics.
Identifiants
pubmed: 39204074
pii: vaccines12080951
doi: 10.3390/vaccines12080951
pmc: PMC11359559
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Sciensano (Belgium)
ID : SC_045
Organisme : Research Foundation - Flanders
ID : 1SDN2524N
Organisme : Ghent University Hospital
ID : KW/2011/CIZ/005/001
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.
Références
MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1163-1166
pubmed: 34437519
N Engl J Med. 2021 Jul 1;385(1):90-92
pubmed: 33852796
J Clin Med. 2021 Nov 24;10(23):
pubmed: 34884205
N Engl J Med. 2021 Nov 4;385(19):1761-1773
pubmed: 34525277
Vaccine. 2022 Jun 26;40(30):4046-4056
pubmed: 35660034
Diabetes Metab Res Rev. 2022 Jan;38(1):e3465
pubmed: 33955644
Int J Mol Sci. 2022 Feb 04;23(3):
pubmed: 35163696
J Exp Med. 2007 Oct 1;204(10):2449-60
pubmed: 17875676
Clin Infect Dis. 2009 Feb 15;48(4):443-8
pubmed: 19140756
mSphere. 2022 Aug 31;7(4):e0016922
pubmed: 35862798
Signal Transduct Target Ther. 2022 May 7;7(1):151
pubmed: 35525870
J Immunol Res. 2016;2016:8426874
pubmed: 27493973
Immun Ageing. 2022 Nov 11;19(1):53
pubmed: 36369012
Cells. 2022 Jan 21;11(3):
pubmed: 35159168
Sci Rep. 2022 Aug 12;12(1):13749
pubmed: 35962053
Clin Infect Dis. 2022 Aug 24;75(1):e695-e704
pubmed: 34864935
Am J Transplant. 2023 May;23(5):649-658
pubmed: 36773936
Microbiol Spectr. 2021 Oct 31;9(2):e0017821
pubmed: 34549995
Commun Med (Lond). 2022 Nov 25;2(1):151
pubmed: 36434092
BMJ Open Respir Res. 2022 Jul;9(1):
pubmed: 35793836
J Clin Virol. 2022 Oct;155:105270
pubmed: 36027822
Curr Opin Nephrol Hypertens. 2018 Mar;27(2):70-76
pubmed: 29140820
Vaccine. 2022 Jan 21;40(2):306-315
pubmed: 34933765
Nat Rev Immunol. 2022 Jun;22(6):387-397
pubmed: 35484322
NPJ Vaccines. 2022 Jan 27;7(1):14
pubmed: 35087066
Eur J Gen Pract. 2023 Dec;29(2):2149732
pubmed: 36440533
Biomed Pharmacother. 2022 Sep;153:113287
pubmed: 35728352
Infection. 2022 Jun;50(3):791-793
pubmed: 34855188
Influenza Other Respir Viruses. 2022 Nov;16(6):1066-1071
pubmed: 35962568
Lancet Microbe. 2023 May;4(5):e309-e318
pubmed: 36963419
Cell. 2021 Nov 11;184(23):5699-5714.e11
pubmed: 34735795
Vaccines (Basel). 2022 Feb 08;10(2):
pubmed: 35214717
Immunol Rev. 2022 Sep;310(1):6-26
pubmed: 35661178
Vaccines (Basel). 2022 Jul 09;10(7):
pubmed: 35891267
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Clin Infect Dis. 2021 Dec 6;73(11):2112-2115
pubmed: 33993265
Science. 2022 Aug 19;377(6608):821-822
pubmed: 35981045
Vaccines (Basel). 2022 Aug 20;10(8):
pubmed: 36016250
Viruses. 2022 Oct 26;14(11):
pubmed: 36366456
Vaccine. 2021 Jul 22;39(32):4423-4428
pubmed: 34210573
Immunogenetics. 2023 Jun;75(3):295-307
pubmed: 36752852
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
N Engl J Med. 2020 Dec 17;383(25):2439-2450
pubmed: 33053279